The estimated Net Worth of Yanling Cao is at least 17.1 百万$ dollars as of 5 June 2020. Mr. Cao owns over 360,000 units of Viela Bio stock worth over 208,059$ and over the last 5 years he sold VIE stock worth over 16,920,000$. In addition, he makes 18,045$ as Director at Viela Bio.
Yanling has made over 1 trades of the Viela Bio stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 360,000 units of VIE stock worth 16,920,000$ on 5 June 2020.
The largest trade he's ever made was selling 360,000 units of Viela Bio stock on 5 June 2020 worth over 16,920,000$. On average, Yanling trades about 120,000 units every 0 days since 2019. As of 5 June 2020 he still owns at least 8,322,353 units of Viela Bio stock.
You can see the complete history of Mr. Cao stock trades at the bottom of the page.
Yanling Cao serves as Director of the Company. Mr. Cao is a founding member and Partner of Boyu Capital, or Boyu, and has been in charge of investments and portfolio management in the healthcare sector since March 2011. Prior to Boyu, Mr. Cao was an investment professional at General Atlantic from December 2007 to January 2011 and Goldman Sachs from July 2006 to November 2007, where he worked on a wide range of strategic and financial transactions. Mr. Cao has been a Director at WuXi Biologics (Cayman) Inc., a biologics contract development and manufacturing company, since May 2016. Mr. Cao also serves on the boards of a number of leading pharmaceutical, diagnostic and healthcare service companies in China. Mr. Cao received a B.A. in Economics and Mathematics, summa cum laude, from Middlebury College.
As the Director of Viela Bio, the total compensation of Yanling Cao at Viela Bio is 18,045$. There are 6 executives at Viela Bio getting paid more, with Zhengbin Yao having the highest compensation of 2,747,550$.
Yanling Cao is 36, he's been the Director of Viela Bio since 2018. There are 11 older and no younger executives at Viela Bio. The oldest executive at Viela Bio, Inc. is Chris Nolet, 63, who is the Independent Director.
Yanling's mailing address filed with the SEC is C/O VIELA BIO, INC.,, ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG, MD, 20878.
Over the last 5 years, insiders at Viela Bio have traded over 58,712,400$ worth of Viela Bio stock and bought 1,261,091 units worth 24,062,867$ . The most active insiders traders include Andreas Wicki、Xiaomeng Tong、Plc Astra Zeneca Uk Ltd Ast.... On average, Viela Bio executives and independent directors trade stock every 41 days with the average trade being worth of 6,348$. The most recent stock trade was executed by Aaron Ren on 18 November 2020, trading 2,000 units of VIE stock currently worth 5,680$.
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Viela Bio executives and other stock owners filed with the SEC include: